Literature DB >> 16322111

Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers.

C Rust1, K Bauchmuller, C Bernt, T Vennegeerts, P Fickert, A Fuchsbichler, U Beuers.   

Abstract

BACKGROUND: Bile acid induced apoptosis in hepatocytes can be antagonised by nuclear factor kappaB (NFkappaB) dependent survival pathways. Sulfasalazine modulates NFkappaB in different cell types. We aimed to determine the effects of sulfasalazine and its metabolites sulfapyridine and 5-aminosalicylic acid (5-ASA) on bile acid induced apoptosis in hepatocytes.
METHODS: Apoptosis was determined by caspase assays and immunoblotting, NFkappaB activation by electrophoretic mobility shift assay and reporter gene assays, generation of reactive oxygen species (ROS) fluorometrically, bile secretion gravimetrically, and bile acid uptake radiochemically and by gas chromatography in HepG2-Ntcp cells and isolated perfused rat livers.
RESULTS: Glycochenodeoxycholic acid (GCDCA 75 micromol/l) induced apoptosis was reduced by sulfasalazine dose dependently (1-1000 micromol/l) in HepG2-Ntcp cells whereas its metabolites 5-ASA and sulfapyridine had no effect. Sulfasalazine significantly reduced GCDCA induced activation of caspases 9 and 3. In addition, sulfasalazine activated NFkappaB and decreased GCDCA induced generation of ROS. Bile acid uptake was competitively inhibited by sulfasalazine. In perfused rat livers, GCDCA (25 micromol/l) induced liver injury and extensive hepatocyte apoptosis were significantly reduced by simultaneous administration of 100 micromol/l sulfasalazine: lactate dehydrogenase and glutamate-pyruvate transaminase activities were reduced by 82% and 87%, respectively, and apoptotic hepatocytes were observed only occasionally. GCDCA uptake was reduced by 45 (5)% when sulfasalazine was coadministered. However, when 50% of GCDCA (12.5 micromol/l) was administered alone, marked hepatocyte apoptosis and liver injury were again observed, questioning the impact of reduced GCDCA uptake for the antiapoptotic effect of sulfasalazine.
CONCLUSION: Sulfasalazine is a potent inhibitor of GCDCA induced hepatocyte apoptosis in vitro and in the intact liver.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322111      PMCID: PMC1856116          DOI: 10.1136/gut.2005.077461

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  34 in total

1.  Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane.

Authors:  Tomomi Kuwana; Mason R Mackey; Guy Perkins; Mark H Ellisman; Martin Latterich; Roger Schneiter; Douglas R Green; Donald D Newmeyer
Journal:  Cell       Date:  2002-11-01       Impact factor: 41.582

2.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man.

Authors:  H Schröder; D E Campbell
Journal:  Clin Pharmacol Ther       Date:  1972 Jul-Aug       Impact factor: 6.875

Review 3.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

4.  NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.

Authors:  M Hermisson; M Weller
Journal:  Cell Death Differ       Date:  2003-09       Impact factor: 15.828

5.  Simultaneous determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnover rates in human serum using 13C-labeled bile acids.

Authors:  F Stellaard; M Sackmann; T Sauerbruch; G Paumgartner
Journal:  J Lipid Res       Date:  1984-12-01       Impact factor: 5.922

6.  Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species.

Authors:  Y Miyachi; A Yoshioka; S Imamura; Y Niwa
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

7.  Bile salt-induced hepatocyte apoptosis involves epidermal growth factor receptor-dependent CD95 tyrosine phosphorylation.

Authors:  Roland Reinehr; Dirk Graf; Dieter Häussinger
Journal:  Gastroenterology       Date:  2003-09       Impact factor: 22.682

8.  Sulfasalazine: II. Some notes on the discovery and development of salazopyrin.

Authors:  N Svartz
Journal:  Am J Gastroenterol       Date:  1988-05       Impact factor: 10.864

9.  The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects?

Authors:  O I Aruoma; M Wasil; B Halliwell; B M Hoey; J Butler
Journal:  Biochem Pharmacol       Date:  1987-11-01       Impact factor: 5.858

Review 10.  The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials.

Authors:  G Jones; J Halbert; M Crotty; E M Shanahan; M Batterham; M Ahern
Journal:  Rheumatology (Oxford)       Date:  2003-01       Impact factor: 7.580

View more
  4 in total

1.  Critical Factors in the Assessment of Cholestatic Liver Injury In Vitro.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  Methods Mol Biol       Date:  2015

2.  Phosphatidylinositol-3-kinase p110γ contributes to bile salt-induced apoptosis in primary rat hepatocytes and human hepatoma cells.

Authors:  Simon Hohenester; Anna Gates; Ralf Wimmer; Ulrich Beuers; M Sawkat Anwer; Christian Rust; Cynthia R L Webster
Journal:  J Hepatol       Date:  2010-07-17       Impact factor: 25.083

3.  Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.

Authors:  Joanne M Donkers; Benno Zehnder; Gerard J P van Westen; Mark J Kwakkenbos; Adriaan P IJzerman; Ronald P J Oude Elferink; Ulrich Beuers; Stephan Urban; Stan F J van de Graaf
Journal:  Sci Rep       Date:  2017-11-10       Impact factor: 4.379

4.  Monitoring structural modulation of redox-sensitive proteins in cells with MS-CETSA.

Authors:  Wendi Sun; Lingyun Dai; Han Yu; Brenda Puspita; Tianyun Zhao; Feng Li; Justin L Tan; Yan Ting Lim; Ming Wei Chen; Radoslaw M Sobota; Daniel G Tenen; Nayana Prabhu; Pär Nordlund
Journal:  Redox Biol       Date:  2019-03-14       Impact factor: 11.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.